In the media
September 12, 2023
(French) Techbio: Owkin turns biotech on its head thanks to artificial intelligence
Thanks to AI and the data collected, Thomas Clozel, co-founder of Owkin, wants to treat patients with tumors.
Share to:
About Owkin
Owkin is building the first universal AI co-pilot called K to lay the foundation for Biological Artificial Superintelligence (BASI). This co-pilot integrates a suite of AI agents that decode complex biology, accelerate research, and dramatically increase productivity. Acting as copilots, Owkin K agents will automate drug discovery and diagnostics and power next-generation pharma companies.
Owkin K will be powered by the world’s largest federated multimodal patient data network, a robotized lab, leading AGI technologies, and cutting-edge multimodal foundation models and LLMs.
